Aclimostat

DB16079InvestigationalSmall molecule

Aclimostat is under investigation in clinical trial NCT03254368 (Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes).

Mechanism: Pharmacologically active on Methionine aminopeptidase 2
Curator reviewed
Formula / weight: C₂₆H₄₂N₂O₆ · 478.63 g/mol (avg)
Code names: ZGN-1061

Resolves to

Compound

UNIIX150A3JK8RCAS2082752-83-6ChEMBLCHEMBL4297651

Structure

InChIKeyQJWJPMLDQYEPPW-AUKZVGPFSA-NSMILES[H][C@@]1([C@H](OC)[C@@H](CC[C@]11CO1)OC(=O)N1CC(CCN2CCOCC2)C1)[C@@]1(C)O[C@@H]1CC=C(C)C

Targets

P50579METAP2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Aclimostat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account